SuperX Overview

  • Founded
  • 2016
Founded
  • Status
  • Out of Business
  • Latest Deal Type
  • Liquidation

SuperX General Information

Description

Developer of anti-thrombotic drugs designed to deliver anticoagulation therapies without the risk of bleeding. The company's drugs can be used in the blood coagulation cascade so as to specifically block the thrombosis that causes heart attacks and strokes, enabling healthcare institutions and doctors to treat patients with an ideal anticoagulant treatment for chronic use.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Primary Office
  • Bridge House 25
  • Fiddlebridge Lane, Hertfordshire
  • Hatfield AL10 0SP
  • England, United Kingdom
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

SuperX Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Bankruptcy: Liquidation 06-Apr-2020 0000 Completed Bankruptcy: Liquidation
1. Early Stage VC (Series A) 09-Feb-2017 0000 0000 Completed Startup
To view SuperX’s complete valuation and funding history, request access »